Please sign in to follow a disease.
Focal segmental glomerulosclerosis 4, susceptibility to
MONDO:0012931Any focal segmental glomerulosclerosis in which the cause of the disease is a mutation in the APOL1 gene.
Also known as: APOL1 focal segmental glomerulosclerosis, focal segmental glomerulosclerosis 4, susceptibility to, focal segmental glomerulosclerosis caused by mutation in APOL1, glomerulosclerosis, focal segmental, 4, susceptibility to, FSGS4, end-stage renal disease, nondiabetic, susceptibility to, susceptibility to focal segmental glomerulosclerosis 4
11 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug targets genetic kidney disease in small trial
Disease control OngoingThis study tests a drug called inaxaplin in 42 people with a genetic form of kidney disease linked to the APOL1 gene. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage, and to check for side effects. Participants take the drug as tablets, and…
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Quick genetic test for unborn babies hits a snag: study withdrawn
Knowledge-focused TerminatedThis study aimed to see if a rapid whole genome sequencing test on amniotic fluid could give faster genetic diagnoses for fetuses with suspected genetic diseases. Researchers planned to compare results from amniotic fluid and blood samples from up to 90 families. However, the stu…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:00 UTC